The story of Viagra presents a nuanced case for stakeholders in the medicinal sector. While initially a tremendous success, creating billions, the patent expiration and the subsequent arrival of generic alternatives have significantly affected earnings. This presents questions about the ongoing profitability of analogous medication innovations and